The Icahn School of Medicine at Mount Sinai – The Mount Sinai Liver Cancer Program, ILCA School hosting institution, is situated in New York City, the most ethnically diverse city in the United States.
The Icahn School of Medicine at Mount Sinai has a long-standing interest in the liver cancer that dates back to the creation of the specialty of Hepatology by Mount Sinai icons Hans Popper and Fenton Schaffner, which was accelerated greatly with the creation of the Liver Transplant Program, the first in New York State, in 1988.
The Mount Sinai School of Medicine and Mount Sinai Medical Center have been at the forefront of clinical management of HCC in the United States for at least 20 years, thanks in large part to the unique talents of the Liver Transplant and Surgery Unit headed by Myron Schwartz, along with members of the Division of Oncology and Liver Diseases, Pathology and Radiology.
This programme earned its international reputation in large measure as a consequence of the clinical contributions made in the surgical management of HCC. Parallel to these efforts, Josep M. Llovet, MD, a well-known international expert on HCC came from a leading center of clinical research in Europe to Mount Sinai to study the molecular basis of this tumour, joining a group led by Scott Friedman, MD.
The formal creation of the Mount Sinai Liver Cancer Program in April 2005 resulted from several key developments:
- An internationally andomised and highly successful clinical HCC programme, directed by Myron Schwartz.
- The creation of the Mont Sinai Liver Cancer Program following the recruitment of Josep M. Llovet, as a full time faculty in the Division of Liver Cancer to lead the programme as a Research Director.
- The support and commitment of the Division of Liver Diseases Scott Friedman
- The exceptional scientific productivity of the group with more than 170 papers in past 5 years.
The Mount Sinai Liver Cancer Program earned its international reputation as a consequence of the clinical contributions made in the area of the surgical management of HCC, combined with the growth of its liver transplantation programme and the burgeoning clinical and research activities of the Division of Liver Diseases.
The Mount Sinai Liver Cancer Program has now more than 38 members and has been structured as a multidisciplinary group comprising hepatologists, surgeons, oncologists, pathologists, radiologists, genetics and genomic experts and basic scientists exploring novel models of disease, mechanism of inflammation and signaling, fibrosis and gene therapy.
The HCC programme is leading three active international andomised controlled trials that can advance the management of the disease. It is the only clinical programme being presented in Mount Sinai’s current application for institutional NCI Cancer Center Support Grant, the first NCI application ever to include an HCC component.